Drug intelligence / Profile preview

thalidomide + vinorelbine

Development stage: Unknown
Lead developer: Grünenthal
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of thalidomide and vinorelbine. Thalidomide is an immunomodulatory agent that inhibits angiogenesis and has anti-inflammatory and anti-cancer properties. Vinorelbine is a semi-synthetic vinca alkaloid that interferes with tubulin polymerization, disrupting mitosis in cancer cells. This combination has been studied primarily for the treatment of advanced non-small cell lung cancer.

Targets

CRBN (Cereblon)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on thalidomide + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thalidomide + vinorelbine.

Explore the full profile